Nepadutant Menarini Richerche.
Menarini Richerche is developing nepadutant, an NK2 antagonist, for the potential treatment of asthma and irritable bowel syndrome. The compound is in phase IIa trials in Belgium and Sweden for both these indications [359518].
Ahluwalia
A
A
School of Medicine and Dentistry, Queen Mary and Westfield College, London, UK. a.ahluwalia@mds.qmw.ac.uk
D000818:Animals; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D003109:Colonic Diseases, Functional / Q000188:drug therapy; D006801:Humans; D015288:Neurokinin A / Q000378:metabolism / Q000502:physiology; D010456:Peptides, Cyclic / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D018041:Receptors, Neurokinin-2 / Q000037:antagonists & inhibitors; D013329:Structure-Activity Relationship
D001993:Bronchodilator Agents; C107754:MEN 11420; D010456:Peptides, Cyclic; D018041:Receptors, Neurokinin-2; D015288:Neurokinin A